View Older Stories View More Recent Stories
-
Eli Lilly & Co. (LLY) Misses Q1 EPS by 12c; updates guidance
-
Eli Lilly faces Q1 sales headwinds as incretin gains offset by weakness in other drugs
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.2 puts into quarter results
-
Eli Lilly & Co. (LLY) May 2 weekly 885 straddle priced into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1.7 calls to 1 put into quarter results
-
Hims & Hers shares surge over 40% on Wegovy pact with Novo Nordisk
-
Eli Lilly & Co. (LLY) option implied volatility flat into quarter results
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
Goldman Sachs Reiterates Buy Rating on Eli Lilly (LLY)
-
HSBC Downgrades Eli Lilly (LLY) to Reduce
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
Bernstein on Eli Lilly (LLY): 'Our Top Pick Still Holds'
-
Cantor Fitzgerald Starts Eli Lilly (LLY) at Overweight
-
BMO Capital: 'Eli Lilly (LLY) Positions Orforglipron for a Global Launch'
-
Eli Lilly & Co. (LLY) call put ratio 1.1 calls to 1 put as share price up 15.9%
-
Eli Lilly (LLY) PT Lowered to $900 at BMO Capital
-
Eli Lilly & Co. (LLY) call put ratio 1.4 calls to 1 put as share price up 13%
-
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly shares jump 12% on positive Phase 3 results for oral diabetes drug
-
Eli Lilly & Co. (LLY) Shares Up 13% on GLP-1 Study Update, Trading 832 Handle
-
Eli Lilly & Co. (LLY) oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
-
Bernstein: 'Eli Lilly (LLY) Keeps Taking Share'
-
Pharma stocks slide after Trump signals tariffs on sector
-
Goldman Sachs Upgrades Eli Lilly (LLY) to Buy
-
BofA: 'Weekly GLP-1 TRx growth in March is trending slightly ahead of February'
-
Trump Admin Drops Biden Medicare Obesity Drug Coverage Proposal - Bloomberg
-
BofA highlights 10 stocks to own for Q2
-
Hims & Hers Health (HIMS) expanding access to personalized weight loss care
-
Hims & Hers Health, Inc. (HIMS) said to sell Lilly's Zepbound
-
Bernstein Assesses U.S. Biopharma Stocks Amid Tariff Risks
-
Wells Fargo Releases Regular Quarterly Update to Tactical Ideas List
-
Stocks expected to have increasing option volume: LLY NVO TEM SPY QQQ
-
Lilly's (LLY) Kisunla Fails To Get Eu Approval In Early Alzheimer's
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.3 puts
-
Organovo (ONVO) Provides Business Update
-
Weighing in on obesity: Catalyst-rich 2025 ahead in a growing competitive landscape
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
-
Organovo (ONVO) Announces Close of the Sale of FXR Program to Eli Lilly and Company (LLY)
-
Bernstein on Eli Lilly (LLY): 'We Like the Lead that Retatrutide Has'
-
Investment commitments in U.S. nears $3 trillion since Trump took office
-
Jefferies Reiterates Buy Rating on Eli Lilly (LLY)
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
Bernstein on Eli Lilly (LLY): 'LLY Takes Majority Share & Anti-Cancer Potential for Retatrutide'
-
Cantor Fitzgerald says more options, newer targets will expand obesity market
-
Will Pfizer step into the obesity ring? Wolfe Research answers
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
How could tariffs shake up the pharma sector?
-
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
-
Eli Lilly's (LLY) EBGLYSS single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
-
Teladoc (TDOC) +2% on addition of GLP-1 self-pay option with Lilly

